Turning Baby Teeth Into Cell Therapy - Scorecard - MDSpire

Turning Baby Teeth Into Cell Therapy

SHED cells show early promise as a potential regenerative therapy in cerebral palsy research

  • March 26, 2026

  • 3 min

Share

Clinical Scorecard: Turning Baby Teeth Into Cell Therapy

At a Glance

CategoryDetail
ConditionCerebral Palsy
Key MechanismsNeurotrophic and immunomodulatory properties of SHED cells may support neuronal repair and reduce inflammation.
Target PopulationChildren with cerebral palsy
Care SettingClinical investigation under controlled conditions

Key Highlights

  • SHED cells derived from exfoliated deciduous teeth show potential for treating cerebral palsy.
  • The treatment was generally well tolerated with no serious adverse events reported.
  • Some participants exhibited improvements in motor and functional assessments post-treatment.
  • SHED cells can be collected noninvasively and expanded in laboratory culture.
  • Further research is needed to confirm long-term safety and effectiveness.

Guideline-Based Recommendations

Diagnosis

  • Assess cerebral palsy based on clinical evaluation and history of early brain injury.

Management

  • Current treatment focuses on rehabilitation, physical therapy, and symptom management.

Monitoring & Follow-up

  • Monitor patients for safety and functional outcomes following SHED cell administration.

Risks

  • No serious adverse events linked to SHED administration reported; however, long-term risks remain unknown.

Patient & Prescribing Data

Pediatric patients diagnosed with cerebral palsy.

SHED-based therapy shows promise but requires larger trials for validation.

Clinical Best Practices

  • Consider SHED cells as a noninvasive option for regenerative therapy in pediatric patients.
  • Conduct larger controlled trials to evaluate treatment effectiveness and safety.

References

Original Source(s)

Turning Baby Teeth Into Cell Therapy

  • March 26, 2026

Related Content

Glutathione peroxidase 2 expression in human tumors: a tissue microarray study on 18,555 tumors

Obstacles to Accessing Health Care and Cancer Screening Services

Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura

Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare autosomal recessive condition that causes deficiency of the von Willebrand factor (vWF)-cleaving metalloprotease, ADAMTS13. Recombinant ADAMTS13 (rADAMTS13) is the first FDA-approved product for management of cTTP. This article reviews the pharmacology, pharmacokinetics, efficacy, safety, dosing, administration, and implications for advanced practitioners of rADAMTS13.